108
Participants
Start Date
August 18, 2014
Primary Completion Date
September 15, 2015
Study Completion Date
September 15, 2015
Liraglutide
Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
Metformin
Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
Placebo
Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
NNC0090-2746
NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
Novo Nordisk Investigational Site, Manassas
Novo Nordisk Investigational Site, Oxon Hill
Novo Nordisk Investigational Site, Greensboro
Novo Nordisk Investigational Site, Port Orange
Novo Nordisk Investigational Site, Sanford
Novo Nordisk Investigational Site, Hialeah
Novo Nordisk Investigational Site, Knoxville
Novo Nordisk Investigational Site, Cincinnati
Novo Nordisk Investigational Site, Evanston
Novo Nordisk Investigational Site, Chicago
Novo Nordisk Investigational Site, Tulsa
Novo Nordisk Investigational Site, Houston
Novo Nordisk Investigational Site, Corpus Christi
Novo Nordisk Investigational Site, Albuquerque
Novo Nordisk Investigational Site, Los Angeles
Novo Nordisk Investigational Site, Hawaiian Gardens
Novo Nordisk Investigational Site, Chino
Novo Nordisk Investigational Site, Spring Valley
Novo Nordisk Investigational Site, Eugene
Novo Nordisk Investigational Site, Berlin
Lead Sponsor
Novo Nordisk A/S
INDUSTRY